Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) FCF Margin (2020 - 2025)

Apellis Pharmaceuticals has reported FCF Margin over the past 6 years, most recently at 7.15% for Q4 2025.

  • Quarterly results put FCF Margin at 7.15% for Q4 2025, down 1625.0% from a year ago — trailing twelve months through Dec 2025 was 4.48% (up 1578.0% YoY), and the annual figure for FY2025 was 4.48%, up 1578.0%.
  • FCF Margin for Q4 2025 was 7.15% at Apellis Pharmaceuticals, down from 23.62% in the prior quarter.
  • Over the last five years, FCF Margin for APLS hit a ceiling of 23.62% in Q3 2025 and a floor of 20695.99% in Q2 2021.
  • Median FCF Margin over the past 5 years was 153.2% (2023), compared with a mean of 1446.16%.
  • Peak annual rise in FCF Margin hit 2003789bps in 2022, while the deepest fall reached -43816bps in 2022.
  • Apellis Pharmaceuticals' FCF Margin stood at 186.63% in 2021, then plummeted by -235bps to 624.78% in 2022, then soared by 89bps to 66.93% in 2023, then soared by 114bps to 9.1% in 2024, then tumbled by -179bps to 7.15% in 2025.
  • The last three reported values for FCF Margin were 7.15% (Q4 2025), 23.62% (Q3 2025), and 2.46% (Q2 2025) per Business Quant data.